AFP and hepatocellular carcinoma: When both AFP and anti-GRP78 autoantibody were used simultaneously as biomarkers, 98 (57%) HCC patients (AFP>200 ng/ml) and 132 (76.7%) HCC patients (AFP>20ng/ml) were positive, respectively.